Stroke Patients: Edoxaban's Role in Recurrence Prevention Unveiled
Exploring the Findings from the NOAH-AFNET 6 Trial and Its Implications for Stroke Patients
Topline
A recent subanalysis of the NOAH-AFNET 6 trial reveals that edoxaban, an oral anticoagulant, does not significantly reduce the risk of recurrent stroke in patients with a history of stroke or transient ischemic attack (TIA) while increasing the risk of significant bleeding. This finding prompts a re-evaluation of current treatment practices for s…
Keep reading with a 7-day free trial
Subscribe to Just Healthcare to keep reading this post and get 7 days of free access to the full post archives.